Insmed Incorporated (INSM) Stock

Insmed Incorporated's ARIKAYCE, approved for MAC lung disease, achieved strong revenue growth in Q3 of 2024 and potential for expanded FDA approval, boosting its market opportunity. Brensocatib's NDA filing for bronchiectasis is expected in Q4 2024 and could lead to a U.S. launch by mid-2025. Top-line results from the phase 2b study, using TPIP for the treatment of patients with PAH, expected in the 2nd half of 2025.

BRIDGEWATER, N.J. , Nov. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: Guggenheim's Inaugural Healthcare Innovation Conference in Boston on Monday, November 11, 2024, at 1:00 p.m.

Review Insmed's (INSM) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

INSM posts wider-than-expected Q3 loss. The company plans to meet the FDA before 2024-end to discuss the possibility of an accelerated approval to expand Arikayce's label.

Insmed Incorporated (NASDAQ:INSM ) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Bryan Dunn – Head of Investor Relations Will Lewis – Chair and Chief Executive Officer Sara Bonstein – Chief Financial Officer Martina Flammer – Chief Medical Officer Conference Call Participants Joe Schwartz – Leerink Partners Jessica Fye – JPMorgan Nicole Germino – Truist Securities Jason Zemansky – Bank of America Jennifer Kim – Cantor Jeff Hung – Morgan Stanley Leon Wang – Barclays Steve Willey – Stifel Graig Suvannavejh – Mizuho Operator Thank you for standing by. My name is Jeannie, and I will be your conference operator today.

Insmed (INSM) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to loss of $1.10 per share a year ago.

—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023— —NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth Quarter of 2024 with Potential U.S. Launch Still Expected in Mid-2025— —Expanded U.S. Sales Force is Now Fully Deployed; Focusing on Bronchiectasis Disease-State Awareness and Supporting the Growth of ARIKAYCE Prior to the Anticipated Launch of Brensocatib— —Ends the Third Quarter with ~$1.5 Billion in Cash, Cash Equivalents, and Marketable Securities— —Renegotiates Term Loan with Pharmakon Resulting in a Lower Cost of Capital and an Additional $150 Million in Proceeds to be Received in the Fourth Quarter— —Reiterates 2024 Global ARIKAYCE Revenue Guidance in the Range of $340 Million to $360 Million, Reflecting Double-Digit Growth Compared to 2023— BRIDGEWATER, N.J. , Oct. 31, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.

Company-wide day of service brings together more than 1,000 employees to support over 40 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J. , Oct. 23, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today holds its third annual Global Day of Good, with more than 1,000 employees volunteering simultaneously in their respective communities around the world.

BRIDGEWATER, N.J. , Oct. 17, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its third-quarter 2024 financial results on Thursday, October 31, 2024.